Optimapharm announces Ivana Waller as CEO
On Tuesday, 29th of March, Optimapharm announced that its Board of Directors has unanimously appointed Ivana Waller as Chief Executive Officer (CEO) of the Company, effective 29th March 2022.
“I have been fortunate to work for some great, soulful companies, and to learn from many incredibly inspiring leaders. The exciting challenge ahead of me now is to lead the growth strategy of Optimapharm. I am looking forward to serving my Optimapharm colleagues and our clients, and ultimately the patients in our clinical trials. I feel both elation and gratitude!”
Ivana Waller, Incoming CEO
We Deliver on Your Promises
With over 20 years of clinical research experience, Ivana Waller has held a number of executive leadership positions, setting and executing strategies for global CROs across the USA, Europe and APAC. Throughout her career, Ivana has developed an extensive global expertise in operational delivery of clinical trials and in leading cross-functional/multicultural teams.
A dynamic leader specialized in operational advancement for contract research organizations, rapid expansions, organic growth, acquisitions, and integrations, Ivana also brings living and working experience in USA, Europe and APAC to the table.
Ivana Waller is joining Optimapharm from Advance Clinical, where she has served as Senior Vice President of Global Development and Expansion; Managing Director Europe and Asia Pacific since January 2018. She previously spent 8 years in Clinipace Worldwide, serving as Chief Business Officer, Europe and Middle East from January 2016 till December 2017, and Chief Operating Officer from October 2009 to December 2015. Prior to joining Clinipace Worldwide, Ivana acted as Vice President, Business Operations for more than a decade at MedTrials Inc. in USA.
Mrs. Waller holds a BA in Economics at the University of Texas, USA.
